RDY
Dr. Reddy's Laboratories Ltd.

599
Loading...
Loading...
News
all
press releases
Alvotech Gears Up to Report Q2 Earnings: Here's What to Expect
ALVO preps for Q2 results as investors eye early U.S. traction for Simlandi and Selarsdi, plus pipeline progress.
Zacks·1mo ago
News Placeholder
More News
News Placeholder
Dr. Reddy's Q1 Earnings Beat Estimates, Generics Sales Boost Revenues
RDY reports encouraging first-quarter fiscal 2026 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.
Zacks·2mo ago
News Placeholder
New Strong Sell Stocks for July 18th
ACHC, CNL and RDY have been added to the Zacks Rank #5 (Strong Sell) List on July 18, 2025.
Zacks·2mo ago
News Placeholder
Roku (ROKU) Surges 10.4%: Is This an Indication of Further Gains?
Zacks·3mo ago
News Placeholder
RDY & ALVO Ink Collaboration Deal for Merck's Keytruda Biosimilar
Zacks·3mo ago
News Placeholder
HSBC upgrades Dr Reddy’s on weight loss drug semaglutide-driven earnings rebound
Investing.com -- HSBC upgraded Dr Reddy’s Laboratories to Buy from Hold and raised its target price to INR 1445, citing expectations that sales of semaglutide, a generic version of Novo Nordisk’s blockbuster weight-loss and diabetes drug, will help drive a recovery in earnings growth from fiscal 2027.HSBC’s new target for the U.S.-listed ADR is $16.90, up from $14.44.
investing.com·3mo ago
News Placeholder
Indian drugmakers fall as Trump says pharma tariffs coming in 2 weeks
Investing.com-- Shares of Indian drugmaking firms, especially those with exposure to the U.S., retreated on Tuesday after President Donald Trump said he will announce tariffs on pharmaceutical imports in the next two weeks. 
investing.com·4mo ago
News Placeholder
US reciprocal tariffs weigh on India, analysts say
Investing.com -- U.S. President Trump’s sweeping move to impose reciprocal tariffs on all trading partners, with India facing a 27% duty on its exports, has prompted a mixed reaction from market strategists, who see both insulation and emerging risks for the South Asian economy.
investing.com·5mo ago
News Placeholder
Dr. Reddys enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex & Darzalex Faspro in the U.S., and Europe
Dr. Reddys Laboratories SA, wholly-owned subsidiary of Dr. Reddys Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as...
Business Wire·7mo ago
News Placeholder
Dr. Reddys Q3 & 9MFY25 Financial Results
Dr. Reddys Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and nine months ended December 31, 2024...
Business Wire·8mo ago

Latest RDY News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.